image
Healthcare - Medical - Devices - NASDAQ - US
$ 1.9
21 %
$ 3.46 M
Market Cap
-0.07
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one TLIS stock under the worst case scenario is HIDDEN Compared to the current market price of 1.9 USD, Talis Biomedical Corporation is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one TLIS stock under the base case scenario is HIDDEN Compared to the current market price of 1.9 USD, Talis Biomedical Corporation is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one TLIS stock under the best case scenario is HIDDEN Compared to the current market price of 1.9 USD, Talis Biomedical Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
412 K REVENUE
-88.72%
-66.8 M OPERATING INCOME
41.97%
-62 M NET INCOME
45.13%
-53.2 M OPERATING CASH FLOW
46.83%
-486 K INVESTING CASH FLOW
69.91%
33 K FINANCING CASH FLOW
-91.87%
0 REVENUE
0.00%
-9.58 M OPERATING INCOME
-4.72%
-8.85 M NET INCOME
32.11%
-11.3 M OPERATING CASH FLOW
-76.29%
84 K INVESTING CASH FLOW
180.00%
0 FINANCING CASH FLOW
0.00%
Balance Sheet Talis Biomedical Corporation
image
Current Assets 77.7 M
Cash & Short-Term Investments 76.7 M
Receivables 50 K
Other Current Assets 901 K
Non-Current Assets 17 M
Long-Term Investments 0
PP&E 15.4 M
Other Non-Current Assets 1.54 M
Current Liabilities 8.77 M
Accounts Payable 1.34 M
Short-Term Debt 2.88 M
Other Current Liabilities 4.55 M
Non-Current Liabilities 16.8 M
Long-Term Debt 16.8 M
Other Non-Current Liabilities 0
EFFICIENCY
Earnings Waterfall Talis Biomedical Corporation
image
Revenue 412 K
Cost Of Revenue 41 K
Gross Profit 371 K
Operating Expenses 67.2 M
Operating Income -66.8 M
Other Expenses -4.81 M
Net Income -62 M
RATIOS
90.05% GROSS MARGIN
90.05%
-16217.23% OPERATING MARGIN
-16217.23%
-15050.24% NET MARGIN
-15050.24%
-89.71% ROE
-89.71%
-65.50% ROA
-65.50%
-96.67% ROIC
-96.67%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Talis Biomedical Corporation
image
Net Income -62 M
Depreciation & Amortization 770 K
Capital Expenditures -486 K
Stock-Based Compensation 4.35 M
Change in Working Capital -3.42 M
Others 5.82 M
Free Cash Flow -53.7 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Talis Biomedical Corporation
image
TLIS has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Talis Biomedical Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
103 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
4 months ago
Sep 06, 2024
Bought 37.1 K USD
Leonard Braden Michael
10 percent owner
+ 25000
1.484 USD
4 months ago
Sep 05, 2024
Bought 7.14 K USD
Leonard Braden Michael
10 percent owner
+ 5100
1.4 USD
4 months ago
Sep 03, 2024
Bought 2 K USD
Leonard Braden Michael
10 percent owner
+ 500
4 USD
4 months ago
Aug 30, 2024
Bought 642 USD
Leonard Braden Michael
10 percent owner
+ 151
4.25 USD
4 months ago
Aug 28, 2024
Bought 4.81 K USD
Leonard Braden Michael
10 percent owner
+ 1215
3.9627 USD
4 months ago
Aug 26, 2024
Bought 51.3 K USD
Leonard Braden Michael
10 percent owner
+ 13167
3.8978 USD
3 years ago
Nov 18, 2021
Bought 218 K USD
BAKER BROS. ADVISORS LP
director, 10 percent owner:
+ 50000
4.365 USD
3 years ago
Aug 13, 2021
Sell 211 K USD
Ramakrishnan Ramesh
- 27502
7.66 USD
3 years ago
May 17, 2021
Bought 111 K USD
Scott Randal W.
Director
+ 11000
10.11 USD
3 years ago
May 14, 2021
Bought 91.4 K USD
Scott Randal W.
Director
+ 9000
10.16 USD
3 years ago
Feb 17, 2021
Bought 84.8 K USD
Popovits Kimberly J
Director
+ 5300
16 USD
3 years ago
Feb 17, 2021
Bought 5 M USD
Scott Randal W.
Director
+ 312500
16 USD
3 years ago
Feb 17, 2021
Bought 92.7 M USD
BAKER BROS. ADVISORS LP
director, 10 percent owner:
+ 5792538
16 USD
3 years ago
Feb 17, 2021
Bought 7.32 M USD
BAKER BROS. ADVISORS LP
director, 10 percent owner:
+ 457462
16 USD
3 years ago
Feb 17, 2021
Bought 16 K USD
Ramakrishnan Ramesh
Sr. Vice President, R&D
+ 1000
16 USD
3 years ago
Feb 17, 2021
Bought 1 M USD
Posard Matthew L.
Director
+ 62500
16 USD
3 years ago
Feb 17, 2021
Bought 27.2 K USD
Moody John Roger Jr
Chief Financial Officer
+ 1700
16 USD
3 years ago
Feb 17, 2021
Bought 64 K USD
Liu Douglas
Sr. Vice President, Operations
+ 4000
16 USD
3 years ago
Feb 17, 2021
Bought 32 K USD
Flick Karen E.
Chief of Staff, Sr. VP, Legal
+ 2000
16 USD
7. News
North American Morning Briefing : Global Ad Shares -2- Lundin Mining Announces Sale to Boliden of its Neves-Corvo operation in Portugal and Zinkgruvan operation in Sweden for Up to $1.52 Billion: Lundin To Receive Upfront Cash Consideration of $1.37B Upon Closing; To Also Get up to $150M in Contingent Cash Upon Satisfaction of Condition; Proceeds Will Strengthen Balance Sheet and Support Growth Plans in the Vicuña District Expected Major Events for Monday aAdsList.push('Article'); aAdsListSize.push([300, 250]); aAdsListCA.push(null); 00:01/UK: Nov KPMG and REC UK Report on Jobs 04:30/JPN: Nov Corporate Insolvencies 05:00/JPN: Nov Economy Watchers Survey 07:00/GER: 3Q Labour cost index 15:00/US: Oct Monthly Wholesale Trade 15:00/US: Nov Employment Trends Index 23:50/JPN: Nov Money Stock, Broadly-defined Liquidity All times in GMT. Powered by Kantar Media and Dow Jones. Expected Earnings for Monday Amtech Systems Inc (ASYS) is expected to report $-0.01 for 4Q. Anavex Life Sciences Corp (AVXL) is expected to report $-0.16 for 4Q. Avalon Advanced Materials is expected to report for 4Q. Braze Inc (BRZE) is expected to report $-0.30 for 3Q. Buckle Inc (BKE) is expected to report. C3.ai Inc (AI) is expected to report $-0.60 for 2Q. Casey's General Stores Inc (CASY) is expected to report $4.25 for 2Q. Centene Corp (CNC) is expected to report for Full year. Digital Ally Inc (DGLY) is expected to report for 3Q. Franklin Resources Inc (BEN) is expected to report. Genasys Inc (GNSS) is expected to report $-0.11 for 4Q. Healthequity Inc (HQY) is expected to report $0.24 for 3Q. MongoDB Inc (MDB) is expected to report $-0.83 for 3Q. NexPoint Diversified Real Estate Trust (NXDT) is expected to report for 3Q. North West Co Inc (NWC.T) is expected to report $0.77 for 3Q. Oil-Dri Corp of America (ODC) is expected to report for 1Q. Oracle Corp (ORCL) is expected to report $1.06 for 2Q. Phreesia Inc (PHR) is expected to report $-0.27 for 3Q. Planet Labs PBC (PL) is expected to report $-0.08 for 3Q. Remark Holdings Inc (MARK) is expected to report $-0.19 for 3Q. Rent the Runway Inc (RENT) is expected to report for 3Q. Smart Share Global Ltd - ADR (EM) is expected to report for 3Q. Talis Biomedical Corp (TLIS) is expected to report for 3Q. Titan Pharmaceuticals Inc (TTNP) is expected to report for 3Q. Toll Brothers Inc (TOL) is expected to report $4.34 for 4Q. Vail Resorts (MTN) is expected to report $-4.96 for 1Q. VersaBank is expected to report $0.29 for 4Q. Webco Industries Inc (WEBC) is expected to report for 1Q. Yext Inc (YEXT) is expected to report $0.06 for 3Q. Powered by Kantar Media and Dow Jones. ANALYST RATINGS ACTIONS Altria Raised to Buy From Neutral by B of A Securities Argan Cut to Market Perform From Market Outperform by CJS Securities Asana Raised to Sector Weight From Underweight by Keybanc Brixmor Property Group Raised to Outperform From Market Perform by BMO Capital Deere & Co Cut to Hold From Buy by Jefferies DocuSign Cut to Reduce From Hold by HSBC Dollar General Raised to Buy From Underperform by B of A Securities Duckhorn Portfolio Cut to Hold From Buy by Jefferies EPAM Systems Raised to Buy From Neutral by Goldman Sachs Fortrea Holdings Cut to Neutral From Outperform by Baird GrafTech International Raised to Neutral From Underweight by JP Morgan Hewlett Packard Ent Raised to Buy From Neutral by Citigroup Kennametal Cut to Hold From Buy by Jefferies Molson Coors Beverage Raised to Buy From Neutral by B of A Securities ONE Gas Cut to Neutral From Buy by Ladenburg Thalmann Paccar Cut to Hold From Buy by Jefferies Peloton Interactive Raised to Neutral From Sell by UBS PJT Partners Raised to Neutral From Sell by UBS PotlatchDeltic Raised to Outperform From Market Perform by BMO Capital ProFrac Holding Cut to Underweight From Neutral by JP Morgan Prologis Cut to Underperform From Market Perform by BMO Capital ProPetro Holding Raised to Neutral From Underweight by JP Morgan Republic Services Raised to Outperform From Market Perform by BMO Capital Robinhood Markets Raised to Buy From Neutral by Goldman Sachs SiteOne Landscape Supply Raised to Buy From Hold by Jefferies Smith & Wesson Brands Cut to Hold From Buy by Craig-Hallum Smith & Wesson Brands Cut to Hold From Buy by Lake Street Timken Raised to Buy From Hold by Jefferies WesBanco Raised to Strong Buy From Outperform by Raymond James Weyerhaeuser Raised to Outperform From Market Perform by BMO Capital This article is a text version of a Wall Street Journal newsletter published earlier today. (END) Dow Jones Newswires 12-09-24 0634ET https://www.marketscreener.com - 1 month ago
Why Is Talis Biomedical (TLIS) Stock Down 52% Today? Talis Biomedical (NASDAQ: TLIS ) stock is falling on Wednesday after the company provided investors with an update on its restructuring plans. Talis Biomedical has brought on two new board members in Patricia Ferrari and John Young, Jr. These two have also elected to serve on a special committee focused on the restructuring of the company. investorplace.com - 5 months ago
Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash REDWOOD CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced it has initiated a process to explore strategic alternatives with the goal of maximizing shareholder value. While the Company has made progress developing the Talis One® system, it believes that this is a prudent path forward given current market conditions. globenewswire.com - 1 year ago
7 Small-Cap Stocks to Sell in August Before They Crash and Burn Although speculative enterprises tend to draw in a loyal band of followers, certain circumstances call for decisive action, as these small-cap stocks to avoid in August confirms. Nobody wants to be the guy or gal throwing in the towel. investorplace.com - 1 year ago
Talis Biomedical Corporation (TLIS) Q2 2023 Earnings Call Transcript Talis Biomedical Corporation (NASDAQ:TLIS ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Emily Faucette - Senior Vice President, Corporate Communications & Investor Relations Rob Kelley - Chief Executive Officer Becky Markovich - Interim Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Operator Good day and thank you for standing by. Welcome to the Talis Biomedical Second Quarter Results and Business Update Conference Call. seekingalpha.com - 1 year ago
Talis Biomedical Announces Second Quarter 2023 Financial Results and Business Update REDWOOD CITY, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported financial results for the second quarter ended June 30, 2023, and provided a business update. globenewswire.com - 1 year ago
Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023 REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report second quarter 2023 financial results and provide a business update on Thursday, August 10, 2023, after market close. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). globenewswire.com - 1 year ago
Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO) REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care (POC), today announced that it has appointed Dr. Andrew A. Lukowiak as president and chief scientific officer, effective August 1, 2023. globenewswire.com - 1 year ago
Talis Biomedical Regains Compliance with Nasdaq Minimum Bid Price Requirement REDWOOD CITY, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated July 20, 2023, that the Company has regained compliance with the minimum bid price requirement of at least $1.00 per share under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In order to regain compliance, the Company's common stock was required to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days which the Company satisfied on July 19, 2023. Accordingly, the Notice stated that Nasdaq now considers the matter closed. globenewswire.com - 1 year ago
Talis Biomedical Corporation (TLIS) Q1 2023 Earnings Call Transcript Talis Biomedical Corporation (NASDAQ:TLIS ) Q1 2023 Earnings Conference Call May 11, 2023 6:00 PM ET Company Participants Emily Faucette - Senior Vice President, Corporate Communications & Investor Relations Rob Kelley - Chief Executive Officer Becky Markovich - Interim Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Operator Good day and thank you for standing by. Welcome to the Talis Biomedical's Business Update Conference Call. seekingalpha.com - 1 year ago
Talis Biomedical to Provide Business Update and Financial Results on May 11, 2023 REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will provide a business update and financial results on Thursday, May 11, 2023, after market close. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). globenewswire.com - 1 year ago
Press release Biocartis Group NV: Biocartis appoints Roger Moody as new CEO PRESS RELEASE: INSIDE INFORMATION/ REGULATED INFORMATION11 April 2023, 22:00 CEST Biocartis appoints Roger Moody as new CEO Roger Moody to be a ppointed as new Chief Executive Officer and member of the Board of Directors Herman Verrelst , current Chief Executive Officer , will move into the position of Executive Chairman of the Board of Directors Addit ional extensive experience in the US diagnostic market while leveraging existing knowledge and relationships Mechelen, Belgium, 11 April 202 3 - Biocartis Group NV (the ‘Company' or ‘Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces changes to its executive management. Roger Moody has been appointed to the position of Chief Executive Officer effective 24 April 2023. globenewswire.com - 1 year ago
8. Profile Summary

Talis Biomedical Corporation TLIS

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 3.46 M
Dividend Yield 0.00%
Description Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.
Contact 230 Constitution Drive, Menlo Park, CA, 94025 https://talisbio.com
IPO Date Feb. 12, 2021
Employees 99
Officers Ms. Rebecca Markovich Interim Chief Financial Officer Mr. Liang Li Ph.D. Co-Founder and Director of Technology & Strategy Ms. Margaret Barrett M.S. Controller Gillian Green Company Secretary